HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) encodes a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of RNA-binding proteins. Located at chromosome 10q26.3, this gene produces a protein that plays critical roles in post-transcriptional RNA processing, including alternative splicing, RNA stability, and RNA transport. The protein contains two RNA recognition motifs (RRMs) that enable sequence-specific binding to RNA targets. HNRNPAB is ubiquitously expressed with particularly high levels in the brain, where it participates in neuronal RNA metabolism essential for synaptic function and neuronal health.
The involvement of HNRNPAB in neurodegenerative diseases has become increasingly apparent through research demonstrating its role in proteinopathy syndromes. In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), HNRNPAB participates in stress granule dynamics and RNA metabolism dysregulation. In Alzheimer's disease, the protein influences tau (MAPT) splicing through regulation of exon 10 inclusion, directly linking RNA processing dysregulation to tau pathology. These connections establish HNRNPAB as a relevant player in neurodegeneration research.
| HNRNPAB | |
|---|---|
| Heterogeneous Nuclear Ribonucleoprotein A/B | |
| Gene Symbol | HNRNPAB |
| Full Name | Heterogeneous Nuclear Ribonucleoprotein A/B |
| Chromosome | 10q26.3 |
| NCBI Gene ID | 3182 |
| Ensembl ID | ENSG00000139718 |
| UniProt ID | Q9GZU1 |
| Protein Length | 305 amino acids |
| Molecular Weight | 36 kDa |
The HNRNPAB gene spans approximately 4.5 kilobases on chromosome 10q26.3. The gene consists of 9 exons that encode a 305-amino acid protein with a molecular weight of approximately 36 kDa. The genomic structure is relatively simple, with the coding sequence distributed across the exons in a pattern typical of housekeeping genes involved in RNA metabolism.
The promoter region contains regulatory elements that mediate both constitutive and tissue-specific expression. Alternative splicing generates multiple transcript variants, some of which encode distinct protein isoforms with potentially different functions.
HNRNPAB exhibits broad tissue distribution:
Brain: High expression throughout the brain, with particular abundance in neurons.
Spinal Cord: Significant expression in motor neurons, the cell type affected in ALS.
Systemic Tissues: Expressed in most other tissues at moderate levels.
Cellular Localization: Predominantly nuclear, with some cytoplasmic localization.
The neuronal expression pattern, combined with the protein's role in RNA processing, makes it particularly relevant to neurodegenerative disease research.
HNRNPAB contains several key structural features:
RNA Recognition Motif 1 (RRM1, residues 30-110): The first RRM mediates initial RNA binding with sequence specificity.
RNA Recognition Motif 2 (RRM2, residues 120-200): The second RRM contributes to RNA binding and protein-protein interactions.
C-terminal Region (residues 200-305): Contains additional protein-protein interaction motifs and nuclear localization signals.
Glycine-Rich Region: Contains auxiliary sequences that may enhance RNA binding.
HNRNPAB performs essential functions in RNA metabolism [1]:
HNRNPAB is a key regulator of alternative splicing:
Splice Site Selection: The protein influences the selection of alternative splice sites.
Splicing Enhancer/Silencer Activity: HNRNPAB can act as both enhancer and silencer depending on context.
Tissue-Specific Splicing: Regulates tissue-specific alternative splicing patterns.
Neuron-Specific Targets: Many targets are specifically regulated in neurons.
HNRNPAB affects RNA half-life:
mRNA Stability: Binding can protect mRNAs from degradation.
AU-Rich Elements: Regulates decay of mRNAs containing ARE sequences.
Decay Pathway Selection: Directs RNAs toward specific degradation pathways.
HNRNPAB participates in RNA localization:
Subcellular Distribution: Helps localize specific mRNAs within cells.
Dendritic Transport: Involved in trafficking RNAs to dendritic compartments.
Synaptic Targeting: Some target mRNAs are transported to synapses.
HNRNPAB is recruited to stress granules under cellular stress [2]:
Stress Response: Stress granules are formed in response to various stresses.
mRNA Sequestration: HNRNPAB helps package mRNAs into stress granules.
Translation Regulation: Stress granules regulate translation initiation.
Dynamic Exchange: Proteins exchange between stress granules and cytosol.
HNRNPAB is implicated in ALS pathogenesis [3]:
Splicing Abnormalities: Global splicing dysregulation is a hallmark of ALS.
RNA-Binding Dysfunction: Altered HNRNPAB function may contribute to RNA processing defects.
Target mRNA Changes: Expression of ALS-relevant mRNAs is affected.
Granule Formation: HNRNPAB is recruited to stress granules in ALS models.
RNA Foci Interaction: May interact with C9orf72 repeat RNA foci.
Sequestration: Pathological stress granules may sequester HNRNPAB.
Persistent Granules: Failure to resolve stress granules may contribute to pathology.
Protein Interactions: HNRNPAB interacts with TDP-43, a central ALS protein.
Co-aggregation: Both proteins may be found in pathological inclusions.
Functional Overlap: HNRNPAB may compensate partially for TDP-43 loss.
HNRNPAB has connections to FTD:
Tau Splicing: Regulation of tau exon 10 splicing is relevant to FTD.
Stress Granule Dynamics: Shared mechanisms with ALS.
TDP-43 Pathology: Most FTD cases involve TDP-43 pathology.
RNA Processing: Global RNA processing dysregulation in FTD brains.
HNRNPAB is particularly relevant to AD through tau pathology [4]:
Alternative Exon: Exon 10 inclusion produces 3R tau isoforms.
Splicing Regulation: HNRNPAB regulates exon 10 splicing through binding sites.
4R Tau Imbalance: Alterations in 3R/4R tau ratio affect tau function.
Pathological Implications: Imbalanced tau isoforms contribute to tauopathy.
Splicing Changes: Tau splicing changes with disease progression.
Therapeutic Target: Correcting splicing may be therapeutic.
Biomarker Potential: Splicing patterns may serve as biomarkers.
Parkinson's Disease: Potential involvement in alpha-synuclein-related pathways.
Huntington's Disease: May affect mutant huntingtin RNA processing.
Spinal Muscular Atrophy: RNA processing defects are central to disease.
HNRNPAB regulates splicing through multiple mechanisms [5]:
RNA Recognition: Specific sequence motifs are recognized by RRMs.
Position Effects: Binding position relative to splice sites determines effects.
Cooperative Binding: Often binds in cooperation with other splicing factors.
Splicing Complexes: Associates with spliceosomal components.
Other hnRNPs: Works with other hnRNP proteins.
Other RBPs: Interactions with TDP-43, FUS, and others.
Stress granules are membrane-less organelles [6]:
Initiation: Untranslated mRNPs coalesce to form granules.
Maturation: granules mature through addition of proteins.
Composition: Contain multiple RBPs including HNRNPAB.
Dynamics: proteins exchange with the cytosol.
Clearance Failure: Impaired granule clearance in neurodegeneration.
Toxic Gain of Function: Pathological granules may become toxic.
Sequestration: Essential proteins may be sequestered.
Relationship to Inclusions: Connections to larger pathological inclusions.
HNRNPAB directly regulates tau exon 10 splicing [7]:
Binding Sites: HNRNPAB binds to regulatory sequences in MAPT pre-mRNA.
Enhancer Function: Acts as an enhancer of exon 10 inclusion.
Balance: The 3R/4R ratio is tightly regulated in normal brain.
Splicing Shifts: Disease states shift the 3R/4R ratio.
Binding Alterations: HNRNPAB binding may be altered in disease.
Therapeutic Target: Restoring normal splicing is a therapeutic goal.
Neuronal Cultures: Primary neurons and neuronal cell lines.
ALS Models: Motor neurons derived from patient iPSCs.
Stress Treatments: Various stress conditions to study stress granule dynamics.
Transgenic Models: Mice expressing mutant HNRNPAB.
Knockout Models: HNRNPAB-deficient mice.
Disease Models: Crosses with ALS, AD models.
CLIP-Seq: Mapping HNRNPAB binding sites on RNA.
Splicing Analysis: High-throughput analysis of splicing changes.
Proteomics: Identifying protein interaction networks.
HNRNPAB may serve as a biomarker:
Expression Changes: Altered expression in disease states.
Splicing Targets: Splicing patterns of HNRNPAB targets may indicate disease.
CSF Detection: Potential for CSF-based biomarkers.
Targeting HNRNPAB is being explored:
Splicing Modulation: Correcting splicing dysregulation.
Stress Granule Modulation: Affecting stress granule dynamics.
Protein-Protein Interactions: Disrupting pathological interactions.
Common Variants: SNPs that may influence disease risk.
Rare Variants: Potentially pathogenic variants under investigation.
Expression QTLs: Genetic variants affecting expression.
Disease Associations: GWAS signals in neurodegeneration.
Ethnic Variation: Allele frequencies vary.
Key questions remain:
Complete Target List: What are all the RNA targets of HNRNPAB?
Disease-Specific Functions: How do disease states alter HNRNPAB function?
Therapeutic Targeting: How can HNRNPAB be modulated therapeutically?
Biomarker Development: Can HNRNPAB be used clinically?
Single-Cell Analysis: Understanding cell-type specific functions.
Spatial Transcriptomics: Mapping HNRNPAB functions in tissues.
RNA Therapies: Antisense oligonucleotides targeting HNRNPAB.
van der Ende J, et al. HNRNPAB in RNA processing. Journal of Molecular Biology. 2019. ↩︎
Liu Y, et al. HNRNPAB and stress granule dynamics. Cell Stress and Chaperones. 2017. ↩︎
Kim HJ, et al. RNA binding proteins in ALS and FTD. Nature Reviews Neurology. 2020. ↩︎
Batra R, et al. RNA binding proteins and tauopathy. RNA Biology. 2016. ↩︎
Chen Y, et al. HNRNPAB in alternative splicing. RNA. 2018. ↩︎
Zhang K, et al. Stress granules in ALS. Acta Neuropathologica. 2019. ↩︎
Liu Y, et al. HNRNPAB and tau splicing. Human Molecular Genetics. 2018. ↩︎